S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Stocks are for suckers – try this instead (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The "King Of Quants" sees 10X potential... (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Stocks are for suckers – try this instead (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The "King Of Quants" sees 10X potential... (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Stocks are for suckers – try this instead (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The "King Of Quants" sees 10X potential... (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Stocks are for suckers – try this instead (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
The "King Of Quants" sees 10X potential... (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The "King Of Quants" sees 10X potential... (Ad)
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
NASDAQ:PTCT

PTC Therapeutics - PTCT Stock Forecast, Price & News

$48.44
-0.42 (-0.86%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$48.30
$50.20
50-Day Range
$42.19
$48.86
52-Week Range
$25.01
$55.58
Volume
785,686 shs
Average Volume
817,876 shs
Market Capitalization
$3.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
7.3% Upside
$52.00 Price Target
Short Interest
Bearish
7.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.21mentions of PTC Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$2.91 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.78) to ($3.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

884th out of 1,004 stocks

Pharmaceutical Preparations Industry

432nd out of 489 stocks


PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 5.6%
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Morgan Stanley Reaffirms Their Hold Rating on PTC Therapeutics (PTCT)
PTC Therapeutics CEO Stuart Peltz To Retire; Names Matthew Klein CEO
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
PTC Therapeutics, Inc. (PTCT)
Where PTC Therapeutics Stands With Analysts
PTCT.P - | Stock Price & Latest News | Reuters
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Company Calendar

Last Earnings
2/21/2023
Today
3/31/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+7.3%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$-559,020,000.00
Pretax Margin
-84.07%

Debt

Sales & Book Value

Annual Sales
$698.80 million
Book Value
($4.76) per share

Miscellaneous

Free Float
69,386,000
Market Cap
$3.58 billion
Optionable
Optionable
Beta
0.40

Key Executives

  • Stuart Walter PeltzStuart Walter Peltz
    Chief Executive Officer & Director
  • Matthew B. KleinMatthew B. Klein
    Chief Operating Officer
  • Emily Hill
    Chief Financial Officer
  • Neil Gregory AlmsteadNeil Gregory Almstead
    Chief Technical Operations Officer
  • Ellen Welch
    Chief Scientific Officer













PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2023?

11 equities research analysts have issued 1 year target prices for PTC Therapeutics' stock. Their PTCT share price forecasts range from $35.00 to $70.00. On average, they expect the company's share price to reach $52.00 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2023?

PTC Therapeutics' stock was trading at $38.17 at the start of the year. Since then, PTCT stock has increased by 26.9% and is now trading at $48.44.
View the best growth stocks for 2023 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Tuesday, February, 21st. The biopharmaceutical company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($1.96) by $0.39. The biopharmaceutical company earned $167.41 million during the quarter, compared to analysts' expectations of $183.07 million. The business's quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm posted ($2.03) EPS.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $898.56 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $48.44.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.58 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.79) on an earnings per share basis.

How many employees does PTC Therapeutics have?

The company employs 1,410 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 4/1/2023 by MarketBeat.com Staff